Akadeum Life Sciences in Ann Arbor, a pioneer in buoyancy-based cell separation technology, has announced the successful close of a $20 million-plus financing round.
The round was led by Michigan Capital Network, with strong participation from Arboretum Ventures, NYBC Ventures, and other investors.
The capital infusion comes as Akadeum recently launched a GMP-compliant product suite designed for use in clinical trials — a critical step in advancing next-generation cell therapies.
The company also recently unveiled the integration ability of microbubbles to go into many existing cell therapy manufacturing tools.
“We’re grateful for the support of our investors, who share our belief in a future where everyone can access transformative cell therapies — a future that requires better cell separation technology to unleash its full potential” says Brandon McNaughton, founder and CEO of Akadeum.
The funding will be used to scale commercial operations, and especially support customers entering clinical trials.
The company states it has gained strong industry momentum, with growing interest from leading biopharma and partners, including Catalent, Charles River Laboratories, ElevateBio, and Lonza, who have featured Akadeum’s technology in recent conference talks and poster sessions.
“Akadeum is delivering some of the most innovative and disruptive technologies we’ve seen in this space,” says Paul D’Amato, managing director and CEO at Michigan Capital Network.
“With the company recently winning the Disruptor of the Year Award during Advanced Therapies Week, word is spreading about Akadeum’s platform, which is redefining how cells are isolated and prepared for therapeutic use.”
Akadeum’s proprietary platform has demonstrated therapeutic relevance, including successful use in preclinical animal models for cancer treatment, and is poised for broader adoption in human cell therapy pipelines. The company is seeing adoption due to high-impact data returning from customers.
“The data speaks for itself: Akadeum’s platform consistently delivers more viable cells, higher yields, and easier workflows compared to conventional methods, which are critical advantages in therapeutic manufacturing,” says Dan Kidle, managing partner at Arboretum Ventures.
“This kind of performance isn’t just incremental — it’s transformative, and why we are seeing rapid adoption and commercial momentum. Akadeum’s commitment to quality, scalability, and preserving cell health is setting a new benchmark for the industry.”
For more information, visit here.
